In Section C, individuals will obtain ABBV-744 and oral navitoclax. In Segment D, individuals will obtain ABBV-744 and ruxolitinib. Individuals will obtain treatment until condition progression or even the individuals are unable to tolerate the study drugs. There may be increased treatment load for members During this trial in comparison https://abbv-744-therapeutic-pote35689.develop-blog.com/38784810/the-2-minute-rule-for-is-abbv-744-effective-for-hematologic-cancers